Zobrazeno 1 - 10
of 94
pro vyhledávání: '"BCMA CAR-T"'
Autor:
Yuhan Yan, Yixuan Tu, Qian Cheng, Jian Zhang, Erhua Wang, Zuqun Deng, Yan Yu, Liwen Wang, Rui Liu, Ling Chu, Liqing Kang, Jing Liu, Xin Li
Publikováno v:
Journal of Translational Medicine, Vol 22, Iss 1, Pp 1-13 (2024)
Abstract Background B-cell maturation antigen (BCMA)-targeted chimeric antigen receptor T-cell (CAR T-cell) therapy has exhibited remarkable efficacy in refractory or relapsed multiple myeloma (R/R MM), but recurrence and rapid progression of disease
Externí odkaz:
https://doaj.org/article/a60950bfb0a443be87c9a362b63aaf60
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
Chimeric antigen receptor T-cell (CAR-T) therapy has ushered in a new era for the treatment of multiple myeloma (MM). Numerous clinical studies, especially those involving B-cell maturation antigen (BCMA)-directed CAR-T, have shown remarkable efficac
Externí odkaz:
https://doaj.org/article/daa29df7191644d98b6550d73d379677
Autor:
Saurabh Zanwar, Surbhi Sidana, Leyla Shune, Omar Castaneda Puglianini, Oren Pasvolsky, Rebecca Gonzalez, Danai Dima, Aimaz Afrough, Gurbakhash Kaur, James A. Davis, Megan Herr, Hamza Hashmi, Peter Forsberg, Douglas Sborov, Larry D. Anderson Jr, Joseph P. McGuirk, Charlotte Wagner, Alex Lieberman-Cribbin, Adriana Rossi, Ciara L. Freeman, Frederick L. Locke, Shambavi Richard, Jack Khouri, Yi Lin, Krina K. Patel, Shaji K. Kumar, Doris K. Hansen
Publikováno v:
Journal of Hematology & Oncology, Vol 17, Iss 1, Pp 1-11 (2024)
Abstract Idecabtagene vicleucel (Ide-cel) has demonstrated excellent efficacy and durable responses in patients with relapsed/refractory multiple myeloma (RRMM). However, the outcomes with ide-cel in patients with extramedullary disease (EMD) remain
Externí odkaz:
https://doaj.org/article/681de79c8e1349a19906516ee568e2af
Autor:
Liqiong Liu, Wenxiang Zhu, Ning Liu, Shiting Gong, Qihong Ma, Huanhuan Zhou, Nan Zhong, Wei Dai, Lijun Zhao, Rui Sun, Jianxun Wang, Yuanyuan Shi, Zhi Guo
Publikováno v:
Heliyon, Vol 10, Iss 17, Pp e36955- (2024)
Chimeric antigen receptor T (CAR-T)-cell therapy targeting B-cell maturation antigen (BCMA) is currently one of the promising treatment methods for relapsed/refractory multiple myeloma (MM). Herein, this study is a case report on a 41-year-old male p
Externí odkaz:
https://doaj.org/article/fbd0e7d8e2414c7fb7d3bfccadbdd843
Autor:
Kai Rejeski, Doris K. Hansen, Radhika Bansal, Pierre Sesques, Sikander Ailawadhi, Jennifer M. Logue, Eva Bräunlein, David M. Cordas dos Santos, Ciara L. Freeman, Melissa Alsina, Sebastian Theurich, Yucai Wang, Angela M. Krackhardt, Frederick L. Locke, Emmanuel Bachy, Michael D. Jain, Yi Lin, Marion Subklewe
Publikováno v:
Journal of Hematology & Oncology, Vol 16, Iss 1, Pp 1-13 (2023)
Abstract Background BCMA-directed CAR T-cell therapy (CAR-T) has altered the treatment landscape of relapsed/refractory (r/r) multiple myeloma, but is hampered by unique side effects that can lengthen hospital stays and increase morbidity. Hematologi
Externí odkaz:
https://doaj.org/article/781664a000bf43b0842a034c8f0fd087
Autor:
Wei Li, Binglei Zhang, Weijie Cao, Wenli Zhang, Tiandong Li, Lina Liu, LinPing Xu, Fengcai Gao, Yanmei Wang, Fang Wang, Haizhou Xing, Zhongxing Jiang, Jianxiang Shi, Zhilei Bian, Yongping Song
Publikováno v:
Experimental Hematology & Oncology, Vol 12, Iss 1, Pp 1-19 (2023)
Abstract Background BCMA CAR-T is highly effective for relapsed/refractory multiple myeloma(R/R-MM) and significantly improves the survival of patients. However, the short remission time and high relapse rate of MM patients treated with BCMA CAR-T re
Externí odkaz:
https://doaj.org/article/c65dba6263854701a81e1cfc1117a3dc
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
IntroductionThe emergence of chimeric antigen receptor (CAR)-T therapy targeting B cell maturation antigen (BCMA) has improved the prognosis of patients with multiple myeloma (MM); however, the majority of patients eventually experience relapse.Metho
Externí odkaz:
https://doaj.org/article/792d9fb03c2b4ded9e2d798e59f7f751
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.